Citations

Showing 10 of 108152 citations.

Nonoperative and Operative Soft‐Tissue, Cartilage, and Bony Regeneration and Orthopaedic Biologics of the Shoulder: An Orthoregeneration Network (ON) Foundation Review
Condron, Nolan B. , Kester, Benjamin S., Tokish, John M. , Zumstein, Matthias A. , Gobezie, Reuben, Scheibel, Markus , Cole, Brian J. , Scheibel, Markus Thomas

Mayo Clinic

Arthroscopy | July 20, 2021 | Volume: 37 | Issue: 10 | Pages: 3200-3218

10.1016/j.arthro.2021.06.033 | PMID 34293441 Get It

Abstract Orthoregeneration is defined as a solution for orthopaedic conditions that harnesses the benefits of biology to improve healing, reduce pain, improve function, and optimally, provide an environment for tissue regeneration. Options include drugs, surgical intervention, scaffolds, biologics as a product of cells, and physical and electro‐magnetic stimuli. The goal of regenerative medicine is to enhance the healing of tissue after musculoskeletal injuries as both isolated treatment and adjunct to surgical management, using novel therapies to improve recovery and outcomes. Various orthopaedic biologics (orthobiologics) have been investigated for the treatment of pathology involving the shoulder including the rotator cuff tendons, glenohumeral articular cartilage, glenoid labrum, the joint capsule, and bone. Promising and established treatment modalities include hyaluronic acid (HA); platelet‐rich plasma (PRP) and platelet rich concentrates (PRC); bone marrow aspirate (BMA) comprising mesenchymal stromal cells (MSCs alternatively termed medicinal signaling cells and frequently, misleadingly labelled “mesenchymal stem cells”); MSC harvested from adipose, umbilical, or placental sources; factors including vascular endothelial growth factors (VEGF), basic fibroblast growth factor (FGF), platelet‐derived growth factor (PDGF), transforming growth factor‐beta (TGFβ), bone morphogenic protein (BMP), and matrix metalloproteinases (MMPs); prolotherapy; pulsed electromagnetic field therapy; microfracture and other marrow‐stimulation techniques; biologic resurfacing using acellular dermal allografts, allograft Achilles tendons, allograft lateral menisci, fascia lata autografts, and porcine xenografts; osteochondral autograft or allograft); and autologous chondrocyte implantation (ACI). Studies involving hyaluronic acid, platelet rich plasma, and medicinal signaling cells of various origin tissues have shown mixed results to‐date as isolated treatments and as surgical adjuncts. Despite varied results thus far, there is great potential for improved efficacy with refinement of current techniques and translation of burgeoning preclinical work. Level of Evidence Level V, expert opinion.
What Is the Potential Role of Poly(ADP-Ribose) Polymerase 1 in Parkinson Disease?
Savica, Rodolfo , Benarroch, Eduardo E.

Mayo Clinic

Neurology | July 19, 2021 | Volume: 97 | Issue: 3 | Pages: 121-124

10.1212/wnl.0000000000012287 Get It

Lifetime Cost and Quality-Adjusted Life-Years Across Management Options for Small- and Medium-Sized Sporadic Vestibular Schwannoma
Macielak, Robert J. , Thao, Viengneesee , Marinelli, John P. , Carlson, Matthew L. , Borah, Bijan J. , Moriarty, James P. , Gompel, Jamie J. Van

Mayo Clinic

Otology & Neurotology | July 19, 2021 | Volume: 42 | Issue: 9 | Pages: e1369-e1375

10.1097/mao.0000000000003266 | PMID 34282100 Get It

Objective: Despite the growing emphasis on healthcare costs, limited data address this aspect of care within the vestibular schwannoma (VS) literature. We sought to determine which strategy confers the lowest lifetime cost and greatest quality-adjusted life-years (QALYs) for patients with small- to medium-sized sporadic VS tumors. Study Design: A Markov model was created to determine the most cost-effective management algorithm. Tumor characteristics, magnetic resonance imaging surveillance schedule, treatment outcomes, and health-related quality of life values were derived from previously published data. Cost estimates were based on CMS Fee Schedule reimbursement rates. Setting: Economic Evaluation Service within the Kern Center for the Science of Healthcare Delivery. Patients: Patients diagnosed with small- to medium-sized sporadic VS. Interventions: Upfront microsurgery following diagnosis, upfront radiosurgery following diagnosis, observation with microsurgery reserved for observed tumor growth, and observation with radiosurgery reserved for observed tumor growth. Results: Across patient ages at time of diagnosis ranging from 18 to 70 years, observation with subsequent radiosurgery used for tumor growth was the most cost-effective management algorithm while upfront microsurgery was the least. When presented with a hypothetical 50-year-old patient, the strategy with the lowest lifetime cost and highest QALYs was observation with subsequent radiosurgery reserved for tumor growth ($32,161, 14.11 QALY), followed by observation with microsurgery reserved for tumor growth ($34,503, 13.94 QALY), upfront radiosurgery ($43,456, 14.02 QALY), and lastly, upfront microsurgery ($47,252, 13.60 QALY). Sensitivity analyses varying mortality rates, estimated costs, health-related quality of life, and progression to nonserviceable hearing demonstrated consistent ranking among treatments. Conclusions: When considering initial management of small- and medium-sized sporadic VSs, neither lifetime cost nor QALYs support upfront microsurgery or radiosurgery, even for younger patients. Initial observation with serial imaging, reserving radiosurgery or microsurgery for patients exhibiting tumor growth, confers the greatest potential for optimized lifetime healthcare cost and QALY outcomes.
Super and Nonresponders to Catheter Ablation for Atrial Fibrillation: A Quality-of-Life Assessment Using Patient Reported Outcomes
Farwati, Medhat , Wazni, Oussama M. , Tarakji, Khaldoun G. , Diab, Mohamed , Scandinaro, Anna , Amin, Mustapha, Zmaili, Mohammad , Bazarbashi, Najdat , Dikilitas, Ozan , Nakagawa, Hiroshi , Kanj, Mohamed , Dresing, Thomas , Bhargava, Mandeep , Baranowski, Bryan, Rickard, John , Cantillon, Daniel J. , Tchou, Patrick , Hussein, Ayman A. , Dikilitas, Ozan , Kuroda, Shunsuke , Callahan, Thomas D , Saliba, Walid I.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | July 19, 2021 | Volume: 14 | Issue: 8 | Pages: No page available

10.1161/circep.121.009938 | PMID 34279998 Get It

Background: Atrial fibrillation (AF) ablation targets improvement in quality of life (QoL). Data is scarce on predictors of QoL improvement following ablation. We aimed to investigate the clinical characteristics underlying differential response in QoL after AF ablation (with or without arrhythmia recurrence). Methods: All patients undergoing AF ablation (2013–2016) at our center were prospectively enrolled in a fully automated patient-reported outcomes registry. A large number of variables were collected including AF symptom severity scale and AF burden (as indicated by AF frequency and duration scores). Patients were divided into 3 groups based on self-report of QoL improvement: remarkable (super responders), mild/moderate, and unchanged or worse (nonresponders). Univariable and multivariable logistic regression models assessed clinical characteristics and QoL outcomes. Results: A total of 956 patients were included (25% females, mean age 63.9). Most patients (≈80%) were super responders (n=761), 138 (14.4%) had mild/moderate improvement, and 57 (5.9%) were nonresponders. The strongest predictors of remarkable QoL improvement were freedom of arrhythmia recurrence (OR, 2.42 [95% CI, 1.27–4.59], P =0.007) and lower AF burden at 12 months. Similarly, higher AF burden was significantly associated with clinical nonresponse. In patients with observed clinical recurrence-QoL mismatch, changes in AF burden at 12 months were the main predictors of QoL outcome, with lower burden predicting higher improvement in QoL and vice versa. Conclusions: Most patients derive significant QoL benefit from AF ablation. Freedom from arrhythmia recurrence and lower AF burden predict remarkable QoL improvement following ablation.
Young-Onset Dementia—New Insights for an Underappreciated Problem
Knopman, David S. , Knopman, David S.

Mayo Clinic

JAMA Neurology | July 19, 2021 | Volume: 78 | Issue: 9 | Pages: 1055

10.1001/jamaneurol.2021.1760 | PMID 34279580 Get It

Management practices for asparaginase-associated coagulopathy: a survey of pediatric oncologists
Greenmyer, Jacob R. , Wyatt, Kirk D. , Rodriguez, Vilmarie , Ashrani, Aneel A. , Warad, Deepti , Warad, Deepti M

Mayo Clinic

No container title available | July 19, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.162672036.68071375/v1 Get It

BACKGROUND: Coagulopathy and thrombosis are well-described complications of asparaginase therapy; however, treatment practices in pediatric hematology oncology patients vary widely as evidence-based guidelines for clinical management of these complications in this population are lacking. OBJECTIVE: To assess management practices of asparaginase-related coagulopathy by pediatric hematology oncology (PHO) providers. DESIGN/METHOD: Email survey sent to 2,327 PHO providers primarily practicing in the United States. RESULTS: Two hundred and eighty-five (12.2%) attending physicians completed the survey. Only 4.6% (n=13/285) routinely prescribe prophylactic anticoagulation during induction chemotherapy for leukemia. Slightly more than half (n=145/250, 50.9%) of all providers perform baseline coagulation studies. Most providers that were surveyed (n= 185/285, 64.9%) only replete coagulant factors if the patient experiences bleeding or bruising. One hundred and thirty (n = 130/285, 45.6%) physicians replace low fibrinogen, and the median replacement was 100 mg/dL (range: 40-200 mg/dL) with the median target of at least 100 mg/dL (range: 50-200 mg/dL). A minority of physicians (n=39/250, 13.7%) replace low antithrombin at a median cutoff activity level of 60% (range 40-100 %) with a median target of 75% (range: 40-125 %). CONCLUSION: There is a significant variation in PHO provider practices for monitoring and management of asparaginase-associated hemostatic derangements. Evidence-based guidelines have the potential to standardize practices.
Comparison of electrocardiograms (ECG) waveforms and centralized ECG measurements between a simple 6‐lead mobile ECG device and a standard 12‐lead ECG
Kleiman, Robert , Darpö, Börje , Brown, Randy, Rudo, Todd, Chamoun, Svetlana, Albert, D.J. , Bos, J. Martijn , Ackerman, Michael J. , Bos, Johan Martijn, Bos, Johan M

Mayo Clinic

Annals of Noninvasive Electrocardiology | July 19, 2021 | Volume: 26 | Issue: 6 | Pages: No page available

10.1111/anec.12872 | PMID 34288227 Get It

Abstract Background Interval duration measurements (IDMs) were compared between standard 12‐lead electrocardiograms (ECGs) and 6‐lead ECGs recorded with AliveCor's KardiaMobile 6L, a hand‐held mobile device designed for use by patients at home. Methods Electrocardiograms were recorded within, on average, 15 min from 705 patients in Mayo Clinic's Windland Smith Rice Genetic Heart Rhythm Clinic. Interpretable 12‐lead and 6‐lead recordings were available for 685 out of 705 (97%) eligible patients. The most common diagnosis was congenital long QT syndrome (LQTS, 343/685 [50%]), followed by unaffected relatives and patients (146/685 [21%]), and patients with other genetic heart diseases, including hypertrophic cardiomyopathy (36 [5.2%]), arrhythmogenic cardiomyopathy (23 [3.4%]), and idiopathic ventricular fibrillation (14 [2.0%]). IDMs were performed by a central ECG laboratory using lead II with a semi‐automated technique. Results Despite differences in patient position (supine for 12‐lead ECGs and sitting for 6‐lead ECGs), mean IDMs were comparable, with mean values for the 12‐lead and 6‐lead ECGs for QTcF, heart rate, PR, and QRS differing by 2.6 ms, −5.5 beats per minute, 1.0 and 1.2 ms, respectively. Despite a modest difference in heart rate, intervals were close enough to allow a detection of clinically meaningful abnormalities. Conclusions The 6‐lead hand‐held device is potentially useful for a clinical follow‐up of remote patients, and for a safety follow‐up of patients participating in clinical trials who cannot visit the investigational site. This technology may extend the use of 12‐lead ECG recordings during the current COVID‐19 pandemic as remote patient monitoring becomes more common in virtual or hybrid‐design clinical studies.
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for hepatocellular carcinoma: a meta-analysis
Zhang, Huimei , Chang, Na , Han, Tiantian , Qu, Guangbo , Liu, Haixia , Sun, Chenyu , Cheng, Ce , Zhou, Qin , Sun, Yehuan , Sun, Yehuan , Sun, Chenyu , Han, Tiantian, Ma, Shaodi

Mayo Clinic

Future Oncology | July 19, 2021 | Volume: 17 | Issue: 30 | Pages: 4027-4040

10.2217/fon-2021-0263 | PMID 34278818 Get It

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
Guidon, Amanda C. , Burton, Leeann B , Chwalisz, Bart K. , Hillis, James , Schaller, Teilo , Amato, Anthony A., Warner, Allison Betof , Cho, Tracey , Clardy, Stacey , Dietrich, Jörg , Dougan, Michael , Doughty, Christopher , Dubey, Divyanshu , Guptill, Jeffrey T. , Johnson, Douglas B. , Juel, Vern C. , Kadish, Robert , Kolb, Noah , LeBoeuf, Nicole R. , Linnoila, Jenny, Mammen, Andrew L. , Martinez‐Lage, Maria , Mooradian, Meghan J. , Naidoo, Jarushka , Neilan, Tomas G. , Reardon, David A. , Rubin, Krista M., Santomasso, Bianca , Sullivan, Ryan J. , Woodman, Karin , Zubiri, Leyre , Louv, William C, Reynolds, Kerry L. , Amato, Anthony A. , Betof Warner, Allison , Dougan, Michael , Mooradian, Meghan J , Naidoo, Jarushka , Sullivan, Ryan J , Zubiri, Leyre , Kolb, Noah A , Clardy, Stacey L , Dubey, Divyanshu , Martinez-Lage, Maria , Cho, Tracey A , Brastianos, Priscilla K. , Cohen, Justine Vanessa , Gelfand, Jeffrey M. , Wang, Nancy

Mayo Clinic

Journal for ImmunoTherapy of Cancer | July 19, 2021 | Volume: 9 | Issue: 7 | Pages: e002890

10.1136/jitc-2021-002890 | PMID 34281989 Get It

Expanding the US Food and Drug Administration–approved indications for immune checkpoint inhibitors in patients with cancer has resulted in therapeutic success and immune-related adverse events (irAEs). Neurologic irAEs (irAE-Ns) have an incidence of 1%–12% and a high fatality rate relative to other irAEs. Lack of standardized disease definitions and accurate phenotyping leads to syndrome misclassification and impedes development of evidence-based treatments and translational research. The objective of this study was to develop consensus guidance for an approach to irAE-Ns including disease definitions and severity grading. A working group of four neurologists drafted irAE-N consensus guidance and definitions, which were reviewed by the multidisciplinary Neuro irAE Disease Definition Panel including oncologists and irAE experts. A modified Delphi consensus process was used, with two rounds of anonymous ratings by panelists and two meetings to discuss areas of controversy. Panelists rated content for usability, appropriateness and accuracy on 9-point scales in electronic surveys and provided free text comments. Aggregated survey responses were incorporated into revised definitions. Consensus was based on numeric ratings using the RAND/University of California Los Angeles (UCLA) Appropriateness Method with prespecified definitions. 27 panelists from 15 academic medical centers voted on a total of 53 rating scales (6 general guidance, 24 central and 18 peripheral nervous system disease definition components, 3 severity criteria and 2 clinical trial adjudication statements); of these, 77% (41/53) received first round consensus. After revisions, all items received second round consensus. Consensus definitions were achieved for seven core disorders: irMeningitis, irEncephalitis, irDemyelinating disease, irVasculitis, irNeuropathy, irNeuromuscular junction disorders and irMyopathy. For each disorder, six descriptors of diagnostic components are used: disease subtype, diagnostic certainty, severity, autoantibody association, exacerbation of pre-existing disease or de novo presentation, and presence or absence of concurrent irAE(s). These disease definitions standardize irAE-N classification. Diagnostic certainty is not always directly linked to certainty to treat as an irAE-N (ie, one might treat events in the probable or possible category). Given consensus on accuracy and usability from a representative panel group, we anticipate that the definitions will be used broadly across clinical and research settings.
Future mainstream platform for online adaptive radiotherapy will be using on‐board MR rather than on‐board (CB) CT images
Hyer, Daniel E. , Cai, Bin , Rong, Yi , Rong, Yi , Hyer, Daniel

Mayo Clinic

Journal of Applied Clinical Medical Physics | July 19, 2021 | Volume: 22 | Issue: 7 | Pages: 4-9

10.1002/acm2.13352 | PMID 34278681 Get It